Charles River Laboratories (CRL) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 2, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale James C. Foster, Director sold 24,042 shares at $350.00 ($8.4M).
- Trade date
- Oct 22, 2026
- Disclosed to the SEC
- Oct 26, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All CRL insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
CRL insider transactions (Form 4)
Open-market purchases and sales. 97 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 26SEC | James C. FosterDirector | Sell Plan | 24,04231,596 held (−43%) | $350.00 | $8.4M | -10.2% | — |
| Oct 23SEC | Shannon M. ParisottoCevp, Disc & Safety Assessment | Sell Plan | 2,1564,807 held (−31%) | $344.41 | $743K | -8.7% | — |
| Oct 7SEC | Shannon M. ParisottoCevp, Disc & Safety Assessment | Sell Plan | 9814,807 held (−17%) | $308.44 | $303K | +1.9% | — |
| Oct 2SEC | Glenn ColemanCFOFirst buy | Buy | 1027,762 held (+0%) | $297.43 | $3K | +5.7% | — |
| Aug 27SEC | James C. FosterDirector | Sell Plan | 33,56131,596 held (−52%) | $300.00 | $10.1M | +4.8% | — |
| Aug 20SEC | Shannon M. ParisottoCevp, Disc & Safety Assessment | Sell Plan | 2,0394,807 held (−30%) | $294.12 | $600K | +6.9% | — |
| Aug 20SEC | Nancy C. AndrewsDirector | Sell | 5731,438 held (−28%) | $285.24 | $163K | +10.2% | — |
| Aug 13SEC | Birgit GirshickCEO | Sell Plan | 6,50036,013 held (−15%) | $279.90 | $1.8M | +12.3% | — |
| Aug 13SEC | Shannon M. ParisottoCevp, Disc & Safety Assessment | Sell Plan | 3,7144,807 held (−44%) | $279.66 | $1.0M | +12.4% | — |
| Aug 11SEC | James C. FosterDirector | Sell Plan | 28,73331,596 held (−48%) | $275.00 | $7.9M | +14.3% | — |
| Aug 10SEC | Victoria L. CreamerEvp & Chief People Officer | Sell | 4,17930,051 held (−12%) | $259.16 | $1.1M | +21.3% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 1,27414,878 held (−8%) | $259.07 | $330K | +21.3% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 1,20512,588 held (−9%) | $258.53 | $312K | +21.6% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 90113,977 held (−6%) | $260.63 | $235K | +20.6% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 81013,167 held (−6%) | $261.45 | $212K | +20.2% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 73611,852 held (−6%) | $258.53 | $190K | +21.6% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 62012,334 held (−5%) | $263.94 | $164K | +19.1% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 48211,852 held (−4%) | $265.17 | $128K | +18.5% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 40413,793 held (−3%) | $258.53 | $104K | +21.6% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 21312,954 held (−2%) | $262.37 | $56K | +19.8% | — |
| Aug 6SEC | Shannon M. ParisottoCevp, Disc & Safety Assessment | Sell Plan | 5,0464,807 held (−51%) | $263.00 | $1.3M | +19.5% | — |
| Jul 1SEC | James C. FosterDirector | Sell Plan | 75,00031,596 held (−70%) | $225.00 | $16.9M | +39.7% | — |
| Mar 4SEC | Joseph W. LaplumeEvp, Corp Strategy & DevelopFirst buy | Buy | 2527,448 held (+0%) | $174.54 | $4K | +80.1% | — |
| Jan 20SEC | Joseph W. LaplumeEvp, Corp Strategy & Develop | Sell | 40023,716 held (−2%) | $163.72 | $65K | +92.0% | — |
Similar past setups: not applicable. CRL has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with CRL in the Research Lab
CRL has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Charles River Laboratories insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $52.1M of CRL stock on the open market; P/E 363.8 vs. a sector median of 24.5.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
CRL insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $9.5M | 3 |
| Q3 2026 | $3K | 1 | $25.7M | 17 |
| Q2 2026 | — | 0 | $16.9M | 1 |
| Q1 2026 | $4K | 1 | — | 0 |
| Q4 2025 | — | 0 | — | 0 |
| Q3 2025 | — | 0 | $65K | 1 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Charles River Laboratories insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $52.1M. 10 of 22 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
CRL earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 4, 2026 | +17.3% | Sold $9.5M | -11.0%S&P -2.8% | pending |
| Aug 5, 2026 | +6.6% | None | +13.4%S&P -0.4% | +8.7% |
| May 7, 2026 | -0.7% | None | -2.3%S&P +0.5% | +2.1% |
| Feb 18, 2026 | -25.6% | None | +3.6%S&P +0.2% | -6.5% |
| Jan 13, 2026 | +7.4% | None | -1.1%S&P -0.7% | -25.4% |
| Nov 5, 2025 | -3.4% | None | -3.9%S&P -0.7% | +7.9% |
| Aug 6, 2025 | +11.8% | None | -10.6%S&P +0.7% | +9.5% |
| May 7, 2025 | +12.4% | None | +22.5%S&P +1.1% | +2.4% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
CRL news sentiment trend
Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.
Tone is scored from headline wording only. It describes the news, not where the stock is going.
CRL short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
CRL stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
- 8-K Investor disclosure
- 8-K Earnings release
- 8-K Investor disclosure
- 8-K Earnings release
Insiders at Charles River Laboratories
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| James C. FosterDirector | — | $43.3M | Oct 26, 2026 | 1 of 2 | — |
| Shannon M. ParisottoCevp, Disc & Safety Assessment | — | $4.0M | Oct 23, 2026 | — | — |
| Birgit GirshickCEO | — | $1.8M | Aug 20, 2026 | 1 of 2 | — |
| Michael Gunnar KnellSvp, Finance And Cao | — | $1.7M | Nov 9, 2026 | — | — |
| Victoria L. CreamerEvp & Chief People Officer | — | $1.1M | Aug 10, 2026 | — | — |
| Nancy C. AndrewsDirector | — | $163K | Aug 20, 2026 | — | — |
| Joseph W. LaplumeEvp, Corp Strategy & Develop | $4K | $65K | Aug 11, 2026 | — | — |
| Glenn ColemanCFO | $3K | — | Oct 2, 2026 | — | — |
| Steven BargDirector | — | — | Jun 3, 2026 | — | — |
| Mark MintzEvp, Chief Information Officer | — | — | Jun 2, 2026 | — | — |
| Paul W. GravesDirector | — | — | May 12, 2026 | — | — |
| Craig B. ThompsonDirector | — | — | May 12, 2026 | — | — |
| Virginia M. WilsonDirector | — | — | May 11, 2026 | — | — |
| Reshema Kemps-PolancoDirector | — | — | May 11, 2026 | — | — |
| Mark J. EnyedyDirector | — | — | May 11, 2026 | — | — |
| George Llado Sr.Director | — | — | May 11, 2026 | — | — |
| Martin MacKayDirector | — | — | May 11, 2026 | — | — |
| Abraham CeesayDirector | — | — | May 11, 2026 | — | — |
Board links: companies that share insiders with CRL
Directors and executives who filed Form 4s for CRL and another company in the last 12 months.
- RAPPRapport Therapeutics Abraham Ceesay Director here · CEO at RAPP · latest filing Oct 23, 2026
- REGNRegeneron Pharmaceuticals Craig B. Thompson Director here · Director at REGN · latest filing May 12, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
CRL stock: common questions
Are Charles River Laboratories insiders buying CRL stock?
No. No Charles River Laboratories insider reported an open-market purchase of CRL in the past 12 months. The latest was CFO Glenn Coleman bought $3K of CRL at $297.43 — first open-market purchase in our records.
Are Charles River Laboratories insiders selling CRL stock?
7 insiders reported sales worth $52.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CRL's P/E ratio?
CRL trades at about 363.8 times trailing earnings, compared with a median of 24.5 for the Health Care sector.
What is CRL's 52-week range?
Over the past year CRL has traded between $149.93 and $376.10. It last closed at $314.32 on Nov 20, 2026.